In the third meta-analysis of 17 randomized controlled trials including 13,000 patients with primary hypercholesterolemia receiving PCSK9 inhibitors recorded a reduction of LDL-C level by 57%, total cholesterol by 46%, apo B by 53%, and PSCK9 by 59%. Here, PCSK9 is linked to familial hypercholesterolemia.